Julie R. Brahmer

Also affiliated with Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, University of Baltimore

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

4.1Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 34 papers — median percentile 61. Top paper: “Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer”.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Nature Medicine(2021)10.1038/s41591-021-01541-0

N/A

3.9DataRank · unranked

137 citations

Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs +22 more

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Nature Medicine(2023)10.1038/s41591-023-02598-9

N/A

3.7DataRank · unranked

151 citations

Cheryl Ho, Garth Nicholas, Rosalyn A. Juergens, Adrian G. Sacher, Andrea S. Fung +15 more

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002473

N/A

2.5DataRank · unranked

67 citations

Karisa C. Schreck, Wei Fu, Chen Hu, Alexander Carvajal-González, Roisín M. Connolly +18 more

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

Journal of Investigative Dermatology(2022)10.1016/j.jid.2022.04.020

N/A

1.8DataRank · unranked

30 citations

Isabelle Brown, Rebecca Goldberg, Matthew T. Taylor, Junwen Deng, Varsha Parthasarathy +15 more

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine(2016)10.1056/nejmoa1606774

N/A

1.4DataRank · unranked

9979 citations

Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp +16 more

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine(2015)10.1056/nejmoa1507643

N/A

1.4DataRank · unranked

9414 citations

Luis Paz-Ares, Diane P Holder, David R. Spigel, Martin Steins, Neal E. Ready +38 more

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of Clinical Oncology(2010)10.1200/jco.2009.26.7609

N/A

1.2DataRank · unranked

2920 citations

Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman +15 more

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Nature Medicine(2025)10.1038/s41591-025-03958-3

N/A

0.441DataRank · unranked

15 citations

Paul K. Lee, Reza J. Mehran, Chen Hu, Suqi Ke, Amna Jamali +24 more

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Lung Cancer(2023)10.1016/j.lungcan.2023.107423

Top 72%

0.109DataRank

Top 72%1 citations

Chih–Yuan Hsu, Jennifer G. Whisenant, Melina E. Marmarelis, Carolyn J. Presley, Karen L. Reckamp +24 more

Persistent mutation burden drives sustained anti-tumor immune responses

Nature Medicine(2023)10.1038/s41591-022-02163-w

N/A

0DataRank · unranked

143 citations

Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M. Shao +16 more

Lung tumor–infiltrating Treghave divergent transcriptional profiles and function linked to checkpoint blockade response

Science Immunology(2023)10.1126/sciimmunol.adg1487

N/A

0DataRank · unranked

75 citations

Jiajia Zhang, Laurene S. Cheung, Sydney Connor, Boyang Zhang, Zhen Zeng +34 more

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2994

N/A

0DataRank · unranked

69 citations

Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis M. Taube +12 more

Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1469

N/A

0DataRank · unranked

34 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +28 more

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

Annals of Oncology(2023)10.1016/j.annonc.2023.10.053

N/A

0DataRank · unranked

19 citations

Patrick M. Forde, J.D. Spicer, C. Wang, Shun Lu, Tetsuya Mitsudomi +15 more

Derivation of CD8+ T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis

iScience(2023)10.1016/j.isci.2023.107095

N/A

0DataRank · unranked

9 citations

Valsamo Anagnostou, Kristen A. Marrone, Victor E. Velculescu, Peter A. Jones, Julie R. Brahmer +3 more

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007188

N/A

0DataRank · unranked

9 citations

Peter B. Illei, Bradley Presson, Dipika Singh, Zhen Zeng, Mara Lanis +12 more

Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.23.546338

N/A

0DataRank · unranked

3 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +25 more

Data from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6533117.v1

N/A

0DataRank · unranked

0 citations

Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis M. Taube +12 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0DataRank · unranked

165 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures

Journal of Clinical Investigation(2024)10.1172/jci176567

N/A

0DataRank · unranked

26 citations

Soren Charmsaz, Stephanie Alden, Madelena Brancati, Howard L. Li, Aanika Balaji +38 more

Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS- Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2983

N/A

0DataRank · unranked

14 citations

Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang, Isha Gurumurthy +24 more

Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer

Clinical Lung Cancer(2024)10.1016/j.cllc.2024.12.008

N/A

0DataRank · unranked

13 citations

Joshua E. Reuss, Anna Crawford, Brian Neelon, Jun O. Liu, Julie R. Brahmer +2 more

Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer

The Oncologist(2024)10.1093/oncolo/oyad335

N/A

0DataRank · unranked

2 citations

Yating Wang, Suresh S. Ramalingam, Sheena Bhalla, Zhuoxin Sun, Hossein Borghaei +3 more

Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis

Arthritis Research & Therapy(2025)10.1186/s13075-025-03546-3

N/A

0DataRank · unranked

5 citations

Ami A. Shah, Clifton O. Bingham, Jennifer H. Elisseeff, Joseph C. Murray, Julie R. Brahmer +5 more

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001282

N/A

0DataRank · unranked

166 citations

Valsamo Anagnostou, Tricia R. Cottrell, Kellie N. Smith, Franco Verde, Marianna Zahurak +27 more

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

Nature(2021)10.1038/s41586-021-03752-4

N/A

0DataRank · unranked

552 citations

Jiajia Zhang, Zhicheng Ji, Ajay Vaghasia, Boyang Zhang, Emily Han-Chung Hsiue +50 more

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Nature Communications(2021)10.1038/s41467-021-24994-w

N/A

0DataRank · unranked

480 citations

Jakob Sidenius Johansen, Stephen Cristiano, Jamie E. Medina, Jillian Phallen, Klaus Richter Larsen +33 more

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100220

N/A

0DataRank · unranked

15 citations

Emily Brigham, Kevin J. Psoter, Khinh Ranh Voong, Bairavi Shankar, David S. Ettinger +16 more

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004688

N/A

0DataRank · unranked

139 citations

Jenna VanLiere Canzoniero, Samuel Rosner, Guangfan Zhang, James R. White, Zineb Belcaid +22 more

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

The Oncologist(2022)10.1093/oncolo/oyac140

N/A

0DataRank · unranked

20 citations

Joseph C. Murray, Kevin J. Psoter, Jiajia Zhang, Durrant Barasa, Julie R. Brahmer +14 more

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

Frontiers in Oncology(2022)10.3389/fonc.2022.945798

N/A

0DataRank · unranked

13 citations

Xiaoshan M. Shao, Noushin Niknafs, Archana Balan, Gavin Pereira, Kristen A. Marrone +12 more

Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team

Journal of Cancer Research and Clinical Oncology(2022)10.1007/s00432-022-04299-1

N/A

0DataRank · unranked

11 citations

Ahyoung Kim, Sean Li, Jarushka Naidoo, Laura C. Cappelli, Julie R. Brahmer +3 more

Lung tumor-infiltrating T reg have divergent transcriptional profiles and function linked to checkpoint blockade response

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.12.13.520329

N/A

0DataRank · unranked

0 citations

Jiajia Zhang, Boyang Zhang, Laurene S. Cheung, Zhen Zeng, Christopher Cherry +32 more

Julie R. Brahmer

Indexed papers

Top data-sharing exemplar

Papers